Open main menu

Psychiatrienet β

Clomipramine-hypericum

Revision as of 12:21, 7 May 2009 by Alexandra (talk | contribs)
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from clomipramine to hypericum.[1] [2]

Nietinrijdenbord.png Stop clomipramine
  • Before day 0: gradually reduce dosage of clomipramine to a maximum of 75 mg/day, when this dosage is > 75 mg/day.
  • Day 1: reduce dosage of clomipramine to 50 mg/day.
  • Day 8: reduce dosage of clomipraminde to 25 mg/day.
  • Day 15: stop administration of clomipramine.
Eenrichtingbord.png Start hypericum
  • Day 15-22: a wash-out period of one week is necessary.
  • Day 23: start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • Hypericum slows the metabolism of clomipramine via CYP3A4.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.